We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
+22.06%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$270M
AUM Growth
–
Cap. Flow
+$241M
Cap. Flow %
89.05%
Top 10 Hldgs %
87.61%
Holding
21
New
21
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
TARO
Taro Pharmaceutical Industries Ltd.
TARO
+$39.4M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$31.5M
3
DYAX
DYAX CORPORATION
DYAX
+$26.7M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$25M
5
ACHN
Achillion Pharmaceuticals
ACHN
+$19.8M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 68.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TARO
1
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
$39.7M 14.69%
+267,883
New +$39.4M
ALNY icon
2
Alnylam Pharmaceuticals
ALNY
$36.3B
$33M 12.22%
+340,395
New +$31.5M
DYAX
3
DELISTED
DYAX CORPORATION
DYAX
$30M 11.09%
+2,131,808
New +$26.7M
BCRX icon
4
BioCryst Pharmaceuticals
BCRX
$2.37B
$27.5M 10.17%
+2,261,361
New +$25M
ACHN
5
DELISTED
Achillion Pharmaceuticals
ACHN
$19.9M 7.35%
+1,622,633
New +$19.8M
LJPC
6
DELISTED
La Jolla Pharmaceutical Company
LJPC
$19.6M 7.26%
+1,064,247
New +$12.6M
ARWR icon
7
Arrowhead Research
ARWR
$12.1B
$19.3M 7.13%
+2,610,000
New +$17.8M
DRNA
8
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$18.4M 6.8%
+1,115,981
New +$12.9M
ZSPH
9
DELISTED
ZS PHARMA INC COMS TK (DE)
ZSPH
$15.6M 5.76%
+374,821
New +$14.8M
RLYP
10
DELISTED
RELYPSA INC COM
RLYP
$13.9M 5.13%
+450,239
New +$10.7M
XNPT
11
DELISTED
XENOPORT, INC.
XNPT
$7.39M 2.73%
+842,568
New +$6.19M
VNDA icon
12
Vanda Pharmaceuticals
VNDA
$312M
$7.16M 2.65%
+500,000
New +$5.92M
GYRE icon
13
Gyre Therapeutics
GYRE
$662M
$7.01M 2.59%
+3,385
New +$6.52M
ADVM
14
DELISTED
Adverum Biotechnologies
ADVM
$2.7M 1%
+5,000
New +$1.93M
RPRX
15
DELISTED
Repros Therapeutics Inc.
RPRX
$2.29M 0.85%
+229,364
New +$1.96M
CYTR
16
DELISTED
CytRx Corp
CYTR
$1.93M 0.71%
+117,500
New +$1.83M
ASMB icon
17
Assembly Biosciences
ASMB
$506M
$1.6M 0.59%
+17,000
New +$1.68M
PLX icon
18
Protalix BioTherapeutics
PLX
$191M
$1.55M 0.57%
+84,385
New +$1.81M
LPCN icon
19
Lipocine
LPCN
$17.1M
$1.1M 0.41%
+12,314
New +$1.04M
NVRO
20
DELISTED
NEVRO CORP.
NVRO
$594K 0.22%
+15,356
New +$484K
APEN
21
DELISTED
Apollo Endosurgery, Inc.
APEN
$169K 0.06%
+779
New +$174K

Similar funds

MG
Mather Group Chicago, Illinois $10B AUM 15.14% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OAM
OP Asset Management Helsinki $9.95B AUM 30.22% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

RTW Investments's Q4 2014 Portfolio in Review

Q4 2014 is the first quarter with a 13F filing on record for RTW Investments, which disclosed 21 positions worth $270M. Its ten largest holdings account for 88% of the portfolio.

Its largest position is Taro Pharmaceutical Industries Ltd.: 267,883 shares worth $39.7M.

By sector, the portfolio is most concentrated in Healthcare at 68% of assets.

  • RTW Investments's largest Q4 2014 buy was Taro Pharmaceutical Industries Ltd.: 267,883 shares worth $39.7M.
  • RTW Investments's ten largest holdings make up 88% of its $270M portfolio in Q4 2014.
  • RTW Investments disclosed 21 positions in Q4 2014, its first 13F filing on record.

Based on RTW Investments's 13F filing for Q4 2014, filed 17 Feb 2015.